This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Acetyl hexapeptide-3
- DrugBank Accession Number
- DB11709
- Background
Argireline has been used in trials studying the treatment of wrinkles.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Acetyl hexapeptide-3 (DB11709)
- Weight
- Average: 887.03
Monoisotopic: 886.444320046 - Chemical Formula
- C35H62N14O11S
- Synonyms
- Acetyl hexapeptide-3
- Acetyl hexapeptide-8
- Argireline
- Argireline NP
- Hexapeptide 3
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Derma Instant Youth Acetyl hexapeptide-3 (0.015 mg/30g) + Hyaluronic acid (0.3 mg/30g) Cream Topical Pella Pharmaceuticals Co. ltd 2016-05-12 Not applicable US 
HydroGold 9 Acetyl hexapeptide-3 (0.01 mg/100mg) + Adenosine (0.04 mg/100mg) + Allantoin (0.2 mg/100mg) + Sodium benzoate (0.5 mg/100mg) + Butylene glycol (2 mg/100mg) + Castor oil (0.4 mg/100mg) + Dimethicone (0.01 mg/100mg) + Glycerin (20 mg/100mg) + Gold (0.0001 mg/100mg) + Nicotinamide (2 mg/100mg) + Phenoxyethanol (0.5 mg/100mg) + Potassium chloride (0.01 mg/100mg) + Titanium dioxide (0.43 mg/100mg) + Xanthan gum (0.5 mg/100mg) Patch Topical Bhmbg Global Branding Inc. 2018-03-09 2019-12-31 US Laser Rejuvenation restoring damage skin Acetyl hexapeptide-3 (0.0001 mL/1mL) + Adenosine (0.00004 mL/1mL) + Centella asiatica (0.001 mL/1mL) Cream Topical Universal Cosmetic Co., Ltd 2010-08-19 Not applicable US Ultra Protection Ultra Long-UVA Acetyl hexapeptide-3 (10 mg/50mL) + Centella asiatica (10 mg/50mL) + Hyaluronic acid (10 mg/50mL) + Marine collagen, soluble (10 mg/50mL) + Titanium dioxide (5 mg/50mL) Cream Cutaneous Shantou Youjia E-Commerce Co., Ltd. 2024-02-01 2024-12-31 US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Derma Instant Youth Acetyl hexapeptide-3 (0.015 mg/30g) + Hyaluronic acid (0.3 mg/30g) Cream Topical Pella Pharmaceuticals Co. ltd 2016-05-12 Not applicable US HydroGold 9 Acetyl hexapeptide-3 (0.01 mg/100mg) + Adenosine (0.04 mg/100mg) + Allantoin (0.2 mg/100mg) + Sodium benzoate (0.5 mg/100mg) + Butylene glycol (2 mg/100mg) + Castor oil (0.4 mg/100mg) + Dimethicone (0.01 mg/100mg) + Glycerin (20 mg/100mg) + Gold (0.0001 mg/100mg) + Nicotinamide (2 mg/100mg) + Phenoxyethanol (0.5 mg/100mg) + Potassium chloride (0.01 mg/100mg) + Titanium dioxide (0.43 mg/100mg) + Xanthan gum (0.5 mg/100mg) Patch Topical Bhmbg Global Branding Inc. 2018-03-09 2019-12-31 US Laser Rejuvenation restoring damage skin Acetyl hexapeptide-3 (0.0001 mL/1mL) + Adenosine (0.00004 mL/1mL) + Centella asiatica (0.001 mL/1mL) Cream Topical Universal Cosmetic Co., Ltd 2010-08-19 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Oligopeptides
- Alternative Parents
- Glutamic acid and derivatives / Glutamine and derivatives / Methionine and derivatives / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Gamma amino acids and derivatives / Medium-chain fatty acids / Amino fatty acids / N-acyl amines / Unsaturated fatty acids show 17 more
- Substituents
- Acetamide / Aliphatic acyclic compound / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-oligopeptide / Amine / Amino acid / Amino acid or derivatives / Amino fatty acid / Carbonyl group show 35 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- L4EL31FWIL
- CAS number
- 616204-22-9
- InChI Key
- AJLNZWYOJAWBCR-OOPVGHQCSA-N
- InChI
- InChI=1S/C35H62N14O11S/c1-18(20(45-19(2)50)9-12-27(52)53)44-23(10-13-28(54)55)31(58)49-25(14-17-61-3)33(60)48-24(8-11-26(36)51)32(59)47-22(7-5-16-43-35(40)41)30(57)46-21(29(37)56)6-4-15-42-34(38)39/h20-25,44H,1,4-17H2,2-3H3,(H2,36,51)(H2,37,56)(H,45,50)(H,46,57)(H,47,59)(H,48,60)(H,49,58)(H,52,53)(H,54,55)(H4,38,39,42)(H4,40,41,43)/t20-,21-,22-,23-,24-,25-/m0/s1
- IUPAC Name
- (4S)-5-{[(1S)-1-{[(1S)-1-{[(1S)-1-{[(1S)-4-carbamimidamido-1-{[(1S)-4-carbamimidamido-1-carbamoylbutyl]carbamoyl}butyl]carbamoyl}-3-carbamoylpropyl]carbamoyl}-3-(methylsulfanyl)propyl]carbamoyl}-3-carboxypropyl]amino}-4-acetamidohex-5-enoic acid
- SMILES
- CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=C)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 71587772
- PubChem Substance
- 347828074
- ChemSpider
- 32700146
- 1314329
- Wikipedia
- Acetyl_hexapeptide-3
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Wrinkles 1 2 Terminated Treatment Focal Dystonia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Patch Topical Cream Topical Cream Cutaneous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0981 mg/mL ALOGPS logP -2.9 ALOGPS logP -9.8 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 3.55 Chemaxon pKa (Strongest Basic) 12.09 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 18 Chemaxon Hydrogen Donor Count 16 Chemaxon Polar Surface Area 442.11 Å2 Chemaxon Rotatable Bond Count 33 Chemaxon Refractivity 240.99 m3·mol-1 Chemaxon Polarizability 89.93 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 285.44907 predictedDeepCCS 1.0 (2019) [M+H]+ 287.17276 predictedDeepCCS 1.0 (2019) [M+Na]+ 293.50174 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 20:41 / Updated at June 12, 2020 16:53